Global Phase 3, randomized, controlled trial comparing azenosertib to standard-of-care chemotherapy now enrollingASPENOVA designed as ...
QD 5:2 selected as azenosertib monotherapy pivotal study dose based on favorable benefit-risk profile in DENALI Part 2a, supporting ...
Insights on the effect of Yanghe Decoction on osteosarcoma progression Osteosarcoma (OS) is a highly aggressive primary bone ...
Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration ...
B cash runway to mid-2029, pivotal SCD & AATD programs, and attractive valuation—review risks and opportunities now.
Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) of the Tumorad-01 study declared that a primary endpoint, identifying the maximum tolerated dose, has ...
Cellenkos receives US FDA clearance to initiate phase 1b/2a trial of CK0802 in steroid-refractory graft-versus-host disease: Houston Thursday, May 7, 2026, 18:00 Hrs [IST] Cellenk ...
Welcome to the Microvast Holdings, Inc. First Quarter 2026 Earnings Call. As a reminder, all participants are in a listen-only mode, and the conference is being recorded. I would now like to turn the ...
When CNN first launched in 1980, there were a lot of detractors. Some even derided it as “Chicken Noodle News” instead of ...
UCB will pay up to $2.2bn for Candid Therapeutics, betting on cizutamig and the wider T-cell engager rush in autoimmune disease.
Good afternoon, ladies and gentlemen, and welcome to the Inovio First Quarter 2026 Financial Results Conference Call. [Operator Instructions] This call is being recorded on Wednesday, May 13, 2026. I ...
Cellenkos®, Inc., a clinical stage biotechnology company, pioneering allogeneic, tissue-targeted regulatory T cell (Treg) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results